	Application No.	Applicant(s)	
Notice of Allowability	10/086,176 Examiner	HEMBROUGH ET AL.	
Ť			
	Michael Borin	1631	
The MAILING DATE of this communication apperation apperation allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication GHTS. This application is subject to	plication. If not included not will be mailed in due course. THIS	
1. \boxtimes This communication is responsive to <u>09/20/2004 and 03/02</u>	<u>2/2005</u> .		
2. The allowed claim(s) is/are 1-18.			
3. A The drawings filed on 28 February 2002 are accepted by the	ne Examiner.		
 4. Acknowledgment is made of a claim for foreign priority una) a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Application No		
· ——			
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements	
5. A SUBSTITUTE OATH OR DECLARATION must be submi INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINER es reason(s) why the oath or declara	'S AMENDMENT or NOTICE OF ation is deficient.	
6. CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached			
1) hereto or 2) to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on the drawing he header according to 37 CFR 1.121(ngs in the front (not the back) of d).	
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT R			
Attachment(s) 1. □ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	Patent Application (PTO-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary		
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail Dat	Paper No./Mail Date 7. 🗵 Examiner's Amendment/Comment	
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8. Examiner's Stateme	ent of Reasons for Allowance	
of Biological Material	9. Other	S. Frequencial for Allowalide	

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sima S. Kulkarni on 03/01/2005.

The application has been amended as follows:

Claim 1: at the end of claim, replace "." with -- , wherein the C-terminal peptide comprises at least 23 C-terminal residues of SEQ ID No. 5 or SEQ ID No. 6. --

Claim 2: replace "is" with - occurs during -

Claim 5, line 2: remove "or peptide"

Claim 5, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 6: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 7: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 8, line 2: remove "or peptide"

Application/Control Number: 10/086,176 Page 3

Art Unit: 1631

Claim 8, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 9: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 11: at the end of claim, replace "." with -- , wherein the C-terminal peptide comprises at least 23 C-terminal residues of SEQ ID No. 5 or SEQ ID No. 6. --

Claim 13, line 2: remove "or peptide"

Claim 13, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 14: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 15: replace "anti-proliferative fragment" with -- C-terminal peptide --

Claim 16, line 2: remove "or peptide"

Claim 16, lines 2-3: remove "a homolog thereof, or anti-proliferative fragment thereof"

Claim 17: replace claim with:

-- The method of claim 11 wherein the C-terminal peptide consists of SEQ ID No. 4. --

Art Unit: 1631

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (571) 272-0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, Ph.D., can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael Borin, Ph.D.
Primary Examiner
Art Unit 1631

mlb